Glaukos Corporation (GKOS) Stock Price & How to Invest

Glaukos Corporation is a San Clemente, California ophthalmic medical technology and pharmaceutical company focused on glaucoma, corneal disorders, and retinal disease. It pioneered Micro-Invasive Glaucoma Surgery (MIGS) with the iStent family of implants and has expanded into sustained-release drug delivery with iDose TR (a glaucoma implant) and corneal therapies including Photrexa and the newer Epioxa cross-linking treatment for keratoconus. The company sells through eye surgeons and clinics in the US and internationally, and reported record Q1 2026 net sales of roughly $150.6 million, up about 41% year over year, with its US glaucoma franchise up roughly 58% and iDose TR contributing around $54 million.

The investment picture is a classic growth-versus-profitability tradeoff. Revenue is compounding quickly and management raised full-year 2026 net-sales guidance to roughly $620 million to $635 million, yet Glaukos is still reporting net losses (about $19.8 million, or $0.34 per share, in Q1 2026) as it spends heavily on commercial launches and R&D. It carries roughly $280 million in cash and short-term investments with no debt, which funds those launches, but the stock trades at a rich multiple of sales and a negative P/E, so the valuation leans on continued rapid adoption of iDose TR and Epioxa. Walnut is not an investment adviser; this is descriptive context, not a recommendation.

Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. Reimbursement complexity is a recurring watchpoint, including Medicaid Drug Rebate Program impacts that have muted Photrexa and general pricing pressure in glaucoma devices. Competition is intense from Alcon, Sight Sciences, AbbVie, Johnson & Johnson, and others across MIGS and glaucoma drug delivery, and a competitor supply recovery or new launch could erode share. The legacy iStent business has shown flattish trends outside iDose, and international markets face new competitive product trialing. Heavy spending relative to current earnings means execution and continued access to capital both matter.

13 analysts publish price targets on GKOS, averaging $193.62 against a $166.72 price as of August 2026, or +16.1%. The published targets run from $172.00 to $215.00, a narrow spread, and the ratings split 13 buy, 1 hold, 0 sell. Over the last six months there have been 12 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full GKOS forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Glaukos Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. iDose TR ramp. The iDose TR sustained-release glaucoma implant is the single biggest growth driver, contributing around $54 million in Q1 2026 and powering the US glaucoma franchise up roughly 58% year over year. The most optimistic published target, $215.00, assumes this works close to its best case.

The case against. Glaukos is still unprofitable and trades at a high multiple of sales, so any slowdown in iDose TR or Epioxa adoption could pressure the stock sharply. The most pessimistic target, $172.00, is roughly what GKOS is worth if this bites instead.

Read the full bull and bear case on GKOS, including what would have to change to break either one. Walnut is not an investment adviser.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Glaukos Corporation's investor relations page or your broker.

• Revenue (TTM): ~$470M
• Q1 2026 net sales: ~$150.6M (up ~41% YoY)
• 2026 revenue guidance: ~$620M to $635M
• Q1 2026 net loss: ~$19.8M (~$0.34/share)
• Market cap: ~$6B
• Cash and short-term investments: ~$280M (no debt)

Glaukos combines roughly 40% revenue growth with ongoing net losses, so it screens as a high-multiple growth medtech rather than a value name (negative trailing P/E). The debt-free balance sheet and roughly $280 million in cash fund the iDose TR and Epioxa launches. Wall Street price targets in 2026 ranged widely, from about $72 to $165, reflecting disagreement over how quickly the newer products scale.

Other names that sit close to GKOS: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get GKOS exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so GKOS sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where GKOS fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

GKOS is a fast-growing, cash-funded eye-care medtech whose story rides on new-product adoption outpacing competition and reimbursement risk while it works toward profitability.

Whether GKOS is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is GKOS a buy or a sell?, and where the stock could go from here in the GKOS stock forecast.

For income investors, whether GKOS pays a dividend and how the payout looks is covered in does GKOS pay a dividend? And to weigh GKOS against a peer, read the full side-by-side comparisons: GKOS vs ALC and GKOS vs ABBV.